Call us today on
0800 092 2896

Get Advice

Latest News

New drug could limit brain injury damage

A late trial has begun to test a drug which could limit the damage done by traumatic brain injuries (TBI). Conducted by pharma company Vsopharm, the test hopes to show the drug can limit secondary problems that come with brain injuries.

New drug could limit brain injury damage

Traumatic Injuries

In the EU each year 1.6 million people suffer from traumatic brain injuries. Of which 70,000 die and 100,000 suffer from disabilities. TBIs can leave some of the most devastating effects for sufferers including:

  • Cognitive problems
  • Communication difficulties
  • Reduced awareness
  • Emotional & behavioural problems
  • Affected mobility
  • Epilepsy and seizures
  • Weakness of muscles
  • Paralysis

Most TBIs require families and friends of the sufferer to take a large role in the care and welfare post injury. This could include handling their finances if they have suffered cognitive problems and helping to complete basic daily tasks. Doing so however puts a lot of strain on those that do help; financial, emotional and physical.

Sincere Law’s job with any traumatic brain injury is to assemble a team of experts able to properly plan ahead for the sufferer and their family to reduce the physical, emotional and financial strain long term following injury.

 

New Drugs

The new drug being tested has been given the name VAS203 or “Ronopterin” has been enrolled in third stage testing with first estimated results scheduled initially to be mid 2019.The drug’s ingredients assist the production of key enzymes which help brain and body functions.

Phase 2 of the testing was successful following delivery in 6 and 12 month trials ensuring it showed improvements to patients in both the long and short term. The third phase of testing will see VAS203 being given to 232 patients suffering moderate to severe TBI in 35 European countries including Austria, France, Germany, Spain and the UK among others.

Vasopharmss CEO, Mr Christian Wandersee said of the third stage of testing:

“The phase III trial is a key test to confirm our belief in the clinical efficacy of ronopternin (VAS203) and its role in the treatment of moderately to severely injured closed head traumatic brain injury patients and leads us another step closer to bringing a drug for a highly unmet need to market. We believe VAS203 will provide physicians with a real opportunity to improve long-term outcomes for patients with this devastating condition.”

Incorrect prescriptions can cause serious injury - Sincere Law

For more information on brain injuries including TBI, you can visit our brain injury page here. Sincere Law are specialists in serious injury cases. If you, a friend or family member have suffered a serious injury as a result of negligence you can call 0800 092 2896 for free, impartial, confidential, conscientious advice from one of our team.

We also have a contact page where you can get in touch directly. We ensure a professional service with links to the best medical, financial and psychological assistance in the UK. If you need advice on planning through a serious injury, call Sincere Law today.